Articles

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14

Division of Hematology, University Hospital Basel and University of Basel, Switzerland
Division of Hematology, University Hospital Basel and University of Basel, Switzerland
Institute of Pathology, University Hospital Basel and University of Basel, Switzerland
Swiss Group for Clinical Cancer Research, Bern, Switzerland
Hematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland
Oncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland
University Clinic of Hematology and Central Hematology Laboratory, University Hospital Bern, Switzerland
Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Departement Medizin, Luzerner Kantonsspital, Switzerland
Kantonsspital Muensterlingen, Switzerland
Cantonal Hospital Liestal, Switzerland
Division of Hematology, University Hospital Basel and University of Basel, Switzerland
Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
Swiss Group for Clinical Cancer Research, Bern, Switzerland
Swiss Group for Clinical Cancer Research, Bern, Switzerland
Hematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland
Oncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge, UK
Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
Vol. 104 No. 4 (2019): April, 2019 https://doi.org/10.3324/haematol.2018.200014